SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Carmen Márquez-Rebollo, Luisa Vergara-Carrasco, Rosa Díaz-Navarro, Delia Rubio-Fernández, Pablo Francoli-Martínez, Rainel Sánchez-De la Rosa, Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing–Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate, Advances in Therapy, 2014,

    CrossRef

  2. 2
    Christopher J. Michaud, Heather M. Bockheim, Muhammad Nabeel, Timothy E. Daum, Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis, Case Reports in Neurological Medicine, 2014, 2014, 1

    CrossRef

  3. 3
    A. H. Cross, R. T. Naismith, Established and novel disease-modifying treatments in multiple sclerosis, Journal of Internal Medicine, 2014, 275, 4
  4. 4
    Michael D Wiese, Vijayaprakash Suppiah, Catherine O’Doherty, Metabolic and safety issues for multiple sclerosis pharmacotherapy – opportunities for personalised medicine, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 8, 1145

    CrossRef

  5. 5
    Dean M. Wingerchuk, Jonathan L. Carter, Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies, Mayo Clinic Proceedings, 2014, 89, 2, 225

    CrossRef

  6. 6
    Radu Tanasescu, Cris S Constantinescu, Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 4, 621

    CrossRef

  7. 7
    Daniel Ontaneda, Samuel Cohn, Robert J. Fox, Risk stratification and mitigation in multiple sclerosis, Multiple Sclerosis and Related Disorders, 2014, 3, 5, 639

    CrossRef

  8. 8
    Simon A. Broadley, Michael H. Barnett, Mike Boggild, Bruce J. Brew, Helmut Butzkueven, Robert Heard, Suzanne Hodgkinson, Allan G. Kermode, Jeannette Lechner-Scott, Richard A.L. Macdonell, Mark Marriott, Deborah F. Mason, John Parratt, Stephen W. Reddel, Cameron P. Shaw, Mark Slee, Judith Spies, Bruce V. Taylor, William M. Carroll, Trevor J. Kilpatrick, John King, Pamela A. McCombe, John D. Pollard, Ernest Willoughby, Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies, Journal of Clinical Neuroscience, 2014,

    CrossRef

  9. 9
    Lesley J. Scott, Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis, CNS Drugs, 2013, 27, 11, 971

    CrossRef

  10. 10
    Rüdiger Holzapfel, Ist Glatirameracetat dreimal pro Woche ausreichend?, DNP - Der Neurologe und Psychiater, 2013, 14, 10, 25

    CrossRef

  11. 11
    Volker Limmroth, Täglich die Standarddosis oder dreimal pro Woche die doppelte Dosis?, InFo Neurologie & Psychiatrie, 2013, 15, 10, 22

    CrossRef

  12. 12
    Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona, Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis, The Cochrane Library,